Long-Term Once-Daily Tiotropium Respimat® Is Well Tolerated and Maintains Efficacy over 52 Weeks in Patients with Symptomatic Asthma in Japan: A Randomised, Placebo-Controlled Study

• Ken Ohta ,

  * E-mail: kenohta@tokyo-hosp.jp

  Affiliation National Hospital Organization, Tokyo National Hospital, Tokyo, Japan

  ⨯
• Masakazu Ichinose,

  Affiliation Department of Respiratory Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan

  ⨯
• Yuji Tohda,

  Affiliation Department of Respiratory Medicine and Allergology, Kinki University, Faculty of Medicine, Osakasayama City, Japan

  ⨯
• Michael Engel,

  Affiliation TA Respiratory Diseases, Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, Germany

  ⨯
• Petra Moroni-Zentgraf,

  Affiliation TA Respiratory Diseases, Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, Germany

  ⨯
• Satoko Kunimitsu,

  Affiliation Clinical Trial Management Department, Nippon Boehringer Ingelheim Co., Ltd., Tokyo, Japan

  ⨯
• Wataru Sakamoto,

  Affiliation Medical Data Services Department, Nippon Boehringer Ingelheim Co., Ltd., Tokyo, Japan

  ⨯
• Mitsuru Adachi

  Affiliation Department of Clinical Research Center, International University of Health and Welfare, Sanno Hospital, Tokyo, Japan

  ⨯